Brazil · Delayed Price · Currency is BRL DexCom Statistics
Total Valuation
DexCom has a market cap or net worth of BRL 136.18 billion. The enterprise value is 133.00 billion.
| Market Cap | 136.18B |
| Enterprise Value | 133.00B |
Important Dates
The next estimated earnings date is Thursday, April 23, 2026.
| Earnings Date | Apr 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -1.75% |
| Shares Change (QoQ) | -2.09% |
| Owned by Insiders (%) | 0.37% |
| Owned by Institutions (%) | 96.43% |
| Float | 382.94M |
Valuation Ratios
The trailing PE ratio is 29.56 and the forward PE ratio is 26.27.
| PE Ratio | 29.56 |
| Forward PE | 26.27 |
| PS Ratio | 5.30 |
| PB Ratio | 9.00 |
| P/TBV Ratio | 9.33 |
| P/FCF Ratio | 22.95 |
| P/OCF Ratio | 17.16 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.99, with an EV/FCF ratio of 22.42.
| EV / Earnings | 28.87 |
| EV / Sales | 5.40 |
| EV / EBITDA | 20.99 |
| EV / EBIT | 27.60 |
| EV / FCF | 22.42 |
Financial Position
The company has a current ratio of 1.88, with a Debt / Equity ratio of 0.51.
| Current Ratio | 1.88 |
| Quick Ratio | 1.53 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | 1.17 |
| Debt / FCF | 1.30 |
| Interest Coverage | 49.83 |
Financial Efficiency
Return on equity (ROE) is 34.50% and return on invested capital (ROIC) is 33.98%.
| Return on Equity (ROE) | 34.50% |
| Return on Assets (ROA) | 8.89% |
| Return on Invested Capital (ROIC) | 33.98% |
| Return on Capital Employed (ROCE) | 21.72% |
| Weighted Average Cost of Capital (WACC) | 12.02% |
| Revenue Per Employee | 2.32M |
| Profits Per Employee | 416,863 |
| Employee Count | 11,050 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 3.18 |
Taxes
In the past 12 months, DexCom has paid 1.39 billion in taxes.
| Income Tax | 1.39B |
| Effective Tax Rate | 23.16% |
Stock Price Statistics
The stock price has decreased by -11.62% in the last 52 weeks. The beta is 1.53, so DexCom's price volatility has been higher than the market average.
| Beta (5Y) | 1.53 |
| 52-Week Price Change | -11.62% |
| 50-Day Moving Average | 7.40 |
| 200-Day Moving Average | 7.88 |
| Relative Strength Index (RSI) | 36.41 |
| Average Volume (20 Days) | 1,578 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.14 |
Income Statement
In the last 12 months, DexCom had revenue of BRL 25.68 billion and earned 4.61 billion in profits. Earnings per share was 11.51.
| Revenue | 25.68B |
| Gross Profit | 15.43B |
| Operating Income | 5.02B |
| Pretax Income | 5.99B |
| Net Income | 4.61B |
| EBITDA | 6.41B |
| EBIT | 5.02B |
| Earnings Per Share (EPS) | 11.51 |
Balance Sheet
The company has 11.01 billion in cash and 7.69 billion in debt, with a net cash position of 3.32 billion.
| Cash & Cash Equivalents | 11.01B |
| Total Debt | 7.69B |
| Net Cash | 3.32B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 15.12B |
| Book Value Per Share | 39.31 |
| Working Capital | 10.41B |
Cash Flow
In the last 12 months, operating cash flow was 7.94 billion and capital expenditures -2.00 billion, giving a free cash flow of 5.93 billion.
| Operating Cash Flow | 7.94B |
| Capital Expenditures | -2.00B |
| Depreciation & Amortization | 1.34B |
| Net Borrowing | -6.42B |
| Free Cash Flow | 5.93B |
| FCF Per Share | n/a |
Margins
Gross margin is 60.10%, with operating and profit margins of 19.56% and 17.94%.
| Gross Margin | 60.10% |
| Operating Margin | 19.56% |
| Pretax Margin | 23.35% |
| Profit Margin | 17.94% |
| EBITDA Margin | 24.96% |
| EBIT Margin | 19.56% |
| FCF Margin | 23.11% |
Dividends & Yields
DexCom does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.75% |
| Shareholder Yield | 1.75% |
| Earnings Yield | 3.38% |
| FCF Yield | 4.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 13, 2022. It was a forward split with a ratio of 4.
| Last Split Date | Jun 13, 2022 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
DexCom has an Altman Z-Score of 7.06 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.06 |
| Piotroski F-Score | 6 |